immunity News and Research

RSS

Hollings Cancer Center researcher receives NCI grants for cancer immunotherapy studies

Hollings Cancer Center researcher Jessica Thaxton, Ph.D., is the recipient of two grants totaling $3.4 million from the National Cancer Institute for her work in cancer immunotherapy and cell stress, one of which is part of the Cancer Moonshot Initiative on immunometabolism.

23 Jul 2020

Study uncovers dual role for molecule involved in autoimmune eye disease

The inflammatory molecule interleukin-17A (IL-17A) triggers immune cells that in turn reduce IL-17A's pro-inflammatory activity, according to a study by National Eye Institute researchers.

23 Jul 2020

Neutralizing antibodies isolated from COVID-19 patients can quash SARS-CoV-2

Scientists across the globe are racing to study how antibodies can help suppress SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19).

23 Jul 2020

Researchers recreate pancreatic cancer tissue using 3D-cell culture technique

Pancreatic cancer is a life-threatening disease with very poor survival rates in patients, and--despite various efforts--its treatment remains challenging.

23 Jul 2020

New article sheds light on challenges faced by vaccine developers

With the global pandemic still in full swing, scientists are working to develop a vaccine in record time. While everyone wants an effective vaccine, they don't all agree on how to get there and what "effective" really means.

23 Jul 2020

New regulatory mechanism reveals complex intricacies of plant immune responses

To ensure survival, living organisms are equipped with defensive systems that detect threats and respond with effective counter measures.

23 Jul 2020

Study shows antibodies drop sharply in first three months after mild COVID-19 cases

A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 -- the virus that causes the disease -- drop sharply over the first three months after infection, decreasing by roughly half every 73 days.

23 Jul 2020

Arcturus and Duke-NUS announce approval of clinical trials for COVID-19 vaccine candidate

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, and Duke-NUS Medical School, Singapore's flagship research-intensive graduate entry medical school, today announced that the Clinical Trial Application for COVID-19 vaccine candidate LUNAR-COV19 has been approved to proceed by the Singapore Health Sciences Authority.

22 Jul 2020

Scientists isolate potent SARS-CoV-2 neutralizing antibodies from COVID-19 patients

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing the SARS-CoV-2 virus.

22 Jul 2020

Vitamin D could help suppress excessive T cell-mediated lung inflammation in severe COVID-19

As COVID-19 continues to spread over the world scientists continue to seek the reasons for the difference in disease severity from person to person.

22 Jul 2020

Faster identification and isolation of infected individuals reduce viral transmission

A new analysis of SARS-CoV-2 transmission data in China shows that faster identification and isolation of infected, symptomatic individuals contributed to the shortening of the average serial interval - or the period between the onset of symptoms in successive cases - over time, as fewer opportunities occurred for viral transmission from one infector to more individuals.

22 Jul 2020

Researchers identify potential new combination therapy to treat head and neck cancer

Researchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.

21 Jul 2020

Pfizer/BioNTech COVID-19 vaccine elicits both neutralizing antibodies and T cell response

A new study published on the preprint server medRxiv by a research group from the U.S. and Germany indicates that a novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) induces functional and proinflammatory T cell responses in almost all participants – marking another landmark achievement for this promising vaccine candidate.

21 Jul 2020

Sanford Burnham Prebys receives CIRM award to advance promising drug candidates for COVID-19

Sanford Burnham Prebys Medical Discovery Institute has received an award from the California Institute for Regenerative Medicine to advance promising drug candidates for COVID-19.

21 Jul 2020

New tools developed to test the ability of anti-coronavirus antibodies

Researchers at The Rockefeller University in New York have developed new tools to rapidly test the ability of antibodies to neutralize SARS-CoV-2, the novel coronavirus responsible for the COVID-19 pandemic.

21 Jul 2020

Antibody profile and estimated seroprevalence in COVID-19 infection

A new Swedish study published on the preprint server medRxiv in July 2020 describes the results of using highly sensitive and specific anti-spike antibody tests in a cohort of patients with COVID-19 over a range of disease severity.

21 Jul 2020

Analysis of the SARS-CoV-2 proteome via visual tools

Now, a new study published on the preprint server bioRxiv* in July 2020 shows how this can be advanced at a greater speed by combining experimental results with homology models obtained by high-throughput pipelines. This will help produce new hypotheses that will show novel druggable targets for effective drug development.

21 Jul 2020

Doctor in Israel reinfected with COVID-19 three months after recovering

There is still a lot to learn about coronavirus disease (COVID-19), which is currently ravaging across the globe. Though scientists are slowly gaining a better understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is still unclear if being infected once may provide long-lasting immunity against the novel coronavirus.

20 Jul 2020

New nanoparticle vaccine for SARS-CoV-2 shows protective traits in preclinical study

A new nanoparticle vaccine for SARS-CoV-2, the virus that causes COVID-19, has shown hints of protection and immunity in a preclinical study, safely eliciting the production of antibodies and antiviral T cell responses in mice and pigtail macaques.

20 Jul 2020

COVID-19 vaccine displays protective traits in nonhuman primates

A replicating RNA vaccine, formulated with a lipid-based nanoparticle emulsion that goes by the acronym LION, produces antibodies against the COVID-19 coronavirus in mice and primates with a single immunization. These antibodies potently neutralize the virus.

20 Jul 2020

immunity News and Research

Hollings Cancer Center researcher receives NCI grants for cancer immunotherapy studies

Study uncovers dual role for molecule involved in autoimmune eye disease

Neutralizing antibodies isolated from COVID-19 patients can quash SARS-CoV-2

Researchers recreate pancreatic cancer tissue using 3D-cell culture technique

New article sheds light on challenges faced by vaccine developers

New regulatory mechanism reveals complex intricacies of plant immune responses

Study shows antibodies drop sharply in first three months after mild COVID-19 cases

Arcturus and Duke-NUS announce approval of clinical trials for COVID-19 vaccine candidate

Scientists isolate potent SARS-CoV-2 neutralizing antibodies from COVID-19 patients

Vitamin D could help suppress excessive T cell-mediated lung inflammation in severe COVID-19

Faster identification and isolation of infected individuals reduce viral transmission

Researchers identify potential new combination therapy to treat head and neck cancer

Pfizer/BioNTech COVID-19 vaccine elicits both neutralizing antibodies and T cell response

Sanford Burnham Prebys receives CIRM award to advance promising drug candidates for COVID-19

New tools developed to test the ability of anti-coronavirus antibodies

Antibody profile and estimated seroprevalence in COVID-19 infection

Analysis of the SARS-CoV-2 proteome via visual tools

Doctor in Israel reinfected with COVID-19 three months after recovering

New nanoparticle vaccine for SARS-CoV-2 shows protective traits in preclinical study

COVID-19 vaccine displays protective traits in nonhuman primates

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News